

Anne Marinier

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2450328/anne-marinier-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

1,062
citations

14
h-index

28
g-index

28
ext. papers

1,402
ext. citations

12.1
avg, IF

3.6
L-index

#	Paper	IF	Citations
24	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.. <i>Nature Communications</i> , 2022 , 13, 2801	17.4	1
23	Identification and optimization of molecular glue compounds that inhibit a noncovalent E2 enzyme-ubiquitin complex. <i>Science Advances</i> , 2021 , 7, eabi5797	14.3	4
22	Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. <i>Nature Communications</i> , 2021 , 12, 4688	17.4	1
21	Dual-Target Inhibitors of the Folate Pathway Inhibit Intrinsically Trimethoprim-Resistant DfrB Dihydrofolate Reductases. <i>ACS Medicinal Chemistry Letters</i> , 2020 , 11, 2261-2267	4.3	5
20	Genetic characterization of ABT-199 sensitivity in human AML. <i>Leukemia</i> , 2020 , 34, 63-74	10.7	26
19	Mild and Diazo-Free Synthesis of Trifluoromethyl-Cyclopropanes Using Sulfonium Ylides. <i>Organic Letters</i> , 2019 , 21, 2265-2268	6.2	17
18	Identification of Allosteric Inhibitors against Active Caspase-6. <i>Scientific Reports</i> , 2019 , 9, 5504	4.9	7
17	Enhancing the drug discovery process: Bayesian inference for the analysis and comparison of dose-response experiments. <i>Bioinformatics</i> , 2019 , 35, i464-i473	7.2	5
16	Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2019 , 36, 84-99.e8	24.3	75
15	Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 7400-7416	8.3	6
14	Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric Analogues. <i>ACS Omega</i> , 2019 , 4, 10056-10069	3.9	5
13	Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. <i>Blood Advances</i> , 2019 , 3, 552-563	7.8	14
12	Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. <i>Leukemia</i> , 2018 , 32, 1349-1357	10.7	17
11	Chemogenomic Approach Unveils the Increased Susceptibility of RUNX1-Mutated AML to Glucocorticoids. <i>Blood</i> , 2018 , 132, 4675-4675	2.2	
10	Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	81
9	Chemogenomic Landscape of -mutated AML Reveals Importance of Allele Dosage in Genetics and Glucocorticoid Sensitivity. <i>Clinical Cancer Research</i> , 2017 , 23, 6969-6981	12.9	26
8	Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. <i>Scientific Reports</i> , 2016 , 5, 37581	4.9	14

7	Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. <i>Blood</i> , 2016 , 127, 3054-61	2.2	55
6	High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells. <i>Journal of Clinical Investigation</i> , 2016 , 126, 4569-4584	15.9	30
5	The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. <i>Nature Genetics</i> , 2015 , 47, 1030-7	36.3	95
4	Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. <i>Nature Structural and Molecular Biology</i> , 2015 , 22, 37-43	17.6	94
3	Identification of small molecules that support human leukemia stem cell activity ex vivo. <i>Nature Methods</i> , 2014 , 11, 436-42	21.6	86
2	E2 enzyme inhibition by stabilization of a low-affinity interface with ubiquitin. <i>Nature Chemical Biology</i> , 2014 , 10, 156-163	11.7	58
1	Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. <i>Science</i> , 2014 , 345, 1509-12	33.3	339